In the latest trading session, 0.79 million Elevation Oncology Inc (NASDAQ:ELEV) shares changed hands as the company’s beta touched 1.34. With the company’s most recent per share price at $0.58 changed hands at -$0.03 or -3.95% at last look, the market valuation stands at $34.49M. ELEV’s current price is a discount, trading about -905.17% off its 52-week high of $5.83. The share price had its 52-week low at $0.50, which suggests the last value was 13.79% up since then.
Analysts gave the Elevation Oncology Inc (ELEV) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ELEV as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Elevation Oncology Inc’s EPS for the current quarter is expected to be -0.22.
Elevation Oncology Inc (NASDAQ:ELEV) trade information
Instantly ELEV was in red as seen in intraday trades today. With action -13.15%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 3.70%, with the 5-day performance at -13.15% in the red. However, in the 30-day time frame, Elevation Oncology Inc (NASDAQ:ELEV) is -11.94% down.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 93.56% from its recent market value. According to analyst projections, ELEV’s forecast low is 8 with 10 as the target high. To hit the forecast high, the stock’s price needs a -1624.14% plunge from its current level, while the stock would need to soar -1279.31% for it to hit the projected low.
Elevation Oncology Inc (ELEV) estimates and forecasts
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -52.56%. The 2025 estimates are for Elevation Oncology Inc earnings to increase by 36.80%, but the outlook for the next 5-year period is at 11.33% per year.
Elevation Oncology Inc (NASDAQ:ELEV)’s Major holders
FARALLON CAPITAL MANAGEMENT LLC holds the second largest percentage of outstanding shares, with 6.0971% or 3.6 million shares worth $9.72 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.64 shares estimated at $0.95 million under it, the former controlled 2.77% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.41% of the shares, roughly 1.43 shares worth around $0.83 million.
